Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer.
Adv Ther
; 39(3): 1375-1392, 2022 03.
Article
in En
| MEDLINE
| ID: mdl-35094298
Full text:
1
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Neoadjuvant Therapy
Type of study:
Etiology_studies
/
Health_economic_evaluation
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Female
/
Humans
Language:
En
Journal:
Adv Ther
Journal subject:
TERAPEUTICA
Year:
2022
Type:
Article
Affiliation country:
United States